Advertisement

Neurotherapeutics

, Volume 5, Issue 1, pp 75–85 | Cite as

Vagus nerve stimulation for epilepsy and depression

  • Andrew H. Milby
  • Casey H. Halpern
  • Gordon H. Baltuch
Review Article

Summary

Many patients with epilepsy suffer from persistent seizures despite maximal antiepileptic drug (AED) therapy. Chronic, intermittent vagus nerve stimulation (VNS) has proven to be a safe, effective option for patients suffering from refractory seizures who are not candidates for surgical resection. Although only a small minority of patients will be entirely seizure-free, VNS as an adjunct to medical therapy does appear to provide a significant amount of improvement in quality of life. Reports of antidepressant effects independent of seizure control, along with the use of multiple AEDs in the treatment of depression, has led to the investigation of VNS as a potential adjunctive treatment for major depressive disorder. Both the number of severely depressed patients refractory to available pharmacologic options and the need for repeated treatments and significant side effects associated with electroconvulsive therapy have heightened the interest in VNS for this patient population. Pilot studies of VNS for depression have shown impressive response rates; however, the effect appears to be gradual in onset, as demonstrated by the lack of a favorable response in a short-term, randomized controlled study. Investigation is thus needed to establish the potential role of VNS as an adjunctive treatment for severe depression.

Key Words

Vagus nerve stimulation vagal epilepsy seizure depression 

References

  1. 1.
    ILAE Commission on Neurosurgery of Epilepsy. A global survey on epilepsy surgery, 1980–1990: a report by the Commission on Neurosurgery of Epilepsy, the International League Against Epilepsy. Epilepsia 1997;38:249–255.CrossRefGoogle Scholar
  2. 2.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–319.PubMedCrossRefGoogle Scholar
  3. 3.
    Terry R, Tarver WB, Zabara J. An implantable neurocybemetic prosthesis system. Epilepsia 1990;31 Suppl 2:S33-S37.PubMedCrossRefGoogle Scholar
  4. 4.
    Terry RS, Tarver WB, Zabara J. The implantable neurocybemetic prosthesis system. Pacing Clin Electrophysiol 1991;14:86–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Reid SA. Surgical technique for implantation of the neurocybernetic prosthesis. Epilepsia 1990;31 Suppl 2: S38-S39.PubMedCrossRefGoogle Scholar
  6. 6.
    Uthman BM, Wilder BJ, Penry JK, et al. Treatment of epilepsy by stimulation of the vagus nerve. Neurology 1993;43:1338–1345.PubMedGoogle Scholar
  7. 7.
    Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia 1990;31 Suppl 2:S40-S43.PubMedCrossRefGoogle Scholar
  8. 8.
    Landy HJ, Ramsay RE, Slater J, Casiano RR, Morgan R. Vagus nerve stimulation for complex partial seizures: surgical technique, safety, and efficacy. J Neurosurg 1993;78:26–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002;1:477–482.PubMedCrossRefGoogle Scholar
  10. 10.
    Shafique S, Dalsing MC. Vagus nerve stimulation therapy for treatment of drug-resistant epilepsy and depression. Perspect Vasc Surg Endovasc Ther 2006;18:323–327; discussion 328.PubMedCrossRefGoogle Scholar
  11. 11.
    Hancock JC, Hoover DB, Hougland MW. Distribution of muscarinic receptors and acetylcholinesterase in the rat heart. J Auton Nerv Syst 1987;19:59–66.PubMedCrossRefGoogle Scholar
  12. 12.
    McGregor A, Wheless J, Baumgartner J, Bettis D. Right-sided vagus nerve stimulation as a treatment for refractory epilepsy in humans. Epilepsia 2005;46:91–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Tarver WB, George RE, Maschino SE, Holder LK, Wernicke JF. Clinical experience with a helical bipolar stimulating lead. Pacing Clin Electrophysiol 1992;15:1545–1556.PubMedCrossRefGoogle Scholar
  14. 14.
    Ali II, Pirzada NA, Kanjwal Y, et al. Complete heart block with ventricular asystole during left vagus nerve stimulation for epilepsy. Epilepsy Behav 2004;5:768–771.PubMedCrossRefGoogle Scholar
  15. 15.
    George R, Salinsky M, Kuzniecky R, et al.; First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. Epilepsia 1994;35:637–643.PubMedCrossRefGoogle Scholar
  16. 16.
    Ben-Menachem E, Mañon-Espaillat R, Ristanovic R, et al.; First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. Epilepsia 1994;35:616–626.PubMedCrossRefGoogle Scholar
  17. 17.
    Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002;59 Suppl 4:S3-S14.PubMedGoogle Scholar
  18. 18.
    Carpenter MB. Core text of neuroanatomy, 4th ed. Baltimore: Williams & Wilkins, 1991.Google Scholar
  19. 19.
    Steriade M, Contreras D. Relations between cortical and thalamic cellular events during transition from sleep patterns to paroxysmal activity. J Neurosci 1995;15:623–642.PubMedGoogle Scholar
  20. 20.
    Henry TR, Votaw JR, Pennell PB, et al. Acute blood flow changes and efficacy of vagus nerve stimulation in partial epilepsy. Neurology 1999;52:1166–1173.PubMedGoogle Scholar
  21. 21.
    Ben-Menachem E, Hamberger A, Hedner T, et al. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res 1995;20:221–227.PubMedCrossRefGoogle Scholar
  22. 22.
    Hamberger A, Haglid K, Nyström B, Silfvenius H. Co-variation of free amino acids in human epileptogenic cortex. Neurochem Res 1993;18:519–525.PubMedCrossRefGoogle Scholar
  23. 23.
    Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995;22:53–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998;39:709–714.PubMedCrossRefGoogle Scholar
  25. 25.
    Meldrum B. Amino acid neurotransmitters and new approaches to anticonvulsant drug action. Epilepsia 1984;25 Suppl 2:S140-S149.PubMedCrossRefGoogle Scholar
  26. 26.
    Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia 1990;31 Suppl 2:S7-S19.PubMedCrossRefGoogle Scholar
  27. 27.
    Banzett RB, Guz A, Paydarfar D, Shea SA, Schachter SC, Lansing RW. Cardiorespiratory variables and sensation during stimulation of the left vagus in patients with epilepsy. Epilepsy Res 1999;35: 1–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Krahl SE, Senanayake SS, Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression in rats. Epilepsia 2001;42:586–589.PubMedCrossRefGoogle Scholar
  29. 29.
    Zanchetti A, Wang SC, Moruzzi G. The effect of vagal afferent stimulation on the EEG pattern of the cat. Electroencephalogr Clin Neurophysiol 1952;4:357–361.PubMedCrossRefGoogle Scholar
  30. 30.
    Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization. Brain Res 1967;5:236–249.PubMedCrossRefGoogle Scholar
  31. 31.
    Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia 1998;39:677–686.PubMedCrossRefGoogle Scholar
  32. 32.
    Koo B. EEG changes with vagus nerve stimulation. J Clin Neurophysiol 2001;18:434–441.PubMedCrossRefGoogle Scholar
  33. 33.
    Murphy JV; The Pediatric VNS Study Group. Left vagal nerve stimulation in children with medically refractory epilepsy. J Pediatr 1999; 134:563–566.PubMedCrossRefGoogle Scholar
  34. 34.
    Lundgren J, Amark P, Blennow G, Strömblad LG, Wallstedt L. Vagus nerve stimulation in 16 children with refractory epilepsy. Epilepsia 1998;39:809–813.PubMedCrossRefGoogle Scholar
  35. 35.
    Vonck K, Boon P, D’Havé M, Vandekerckhove T, O’Connor S, De Reuck J. Long-term results of vagus nerve stimulation in refractory epilepsy. Seizure 1999;8:328–334.PubMedCrossRefGoogle Scholar
  36. 36.
    Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 1992;33: 1005–1012.PubMedCrossRefGoogle Scholar
  37. 37.
    Lockard JS, Congdon WC, DuCharme LL. Feasibility and safety of vagal stimulation in monkey model. Epilepsia 1990;31 Suppl 2:S20-S26.PubMedCrossRefGoogle Scholar
  38. 38.
    Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia 1996;37:1111–1116.PubMedCrossRefGoogle Scholar
  39. 39.
    Uthman BM, Wilder BJ, Hammond EJ, Reid SA. Efficacy and safety of vagus nerve stimulation in patients with complex partial seizures. Epilepsia 1990;31 Suppl 2:S44-S50.PubMedCrossRefGoogle Scholar
  40. 40.
    Wilder BJ, Uthman BM, Hammond EJ. Vagal stimulation for control of complex partial seizures in medically refractory epileptic patients. Pacing Clin Electrophysiol 1991;14:108–115.PubMedCrossRefGoogle Scholar
  41. 41.
    Murphy JV, Homig G, Schallert G. Left vagal nerve stimulation in children with refractory epilepsy: preliminary observations. Arch Neurol 1995;52:886–889.PubMedGoogle Scholar
  42. 42.
    Labar D, Nikolov B, Tarver B, Fraser R. Vagus nerve stimulation for symptomatic generalized epilepsy: a pilot study. Epilepsia 1998;39:201–205.PubMedCrossRefGoogle Scholar
  43. 43.
    Boon P, Vonck K, Vandekerckhove T, et al. Vagus nerve stimulation for medically refractory epilepsy; efficacy and cost-benefit analysis. Acta Neurochir (Wien) 1999;141:447–452; discussion 453.CrossRefGoogle Scholar
  44. 44.
    The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995;45:224–230.Google Scholar
  45. 45.
    Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998;51:48–55.PubMedGoogle Scholar
  46. 46.
    Tatum WO, Johnson KD, Goff S, Ferreira JA, Vale FL. Vagus nerve stimulation and drug reduction. Neurology 2001;56:561–563.PubMedGoogle Scholar
  47. 47.
    McLachlan RS, Sadler M, Pillay N, et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor? Eur Neurol 2003;50:16–19.PubMedCrossRefGoogle Scholar
  48. 48.
    Amar AP, DeGiorgio CM, Tarver WB, Apuzzo ML. Long-term multicenter experience with vagus nerve stimulation for intractable partial seizures: results of the XE5 trial. Stereotact Funct Neurosurg 1999;73:104–108.PubMedCrossRefGoogle Scholar
  49. 49.
    Salinsky MC, Uthman BM, Ristanovic RK, Wemicke JF, Tarver WB; Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for the treatment of medically intractable seizures: results of a 1-year open-extension trial. Arch Neurol 1996;53:1176–1180.PubMedGoogle Scholar
  50. 50.
    Morris GL 3rd, Mueller WM; The Vagus Nerve Stimulation Study Group E01-E05. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy [Erratum in: Neurology 2000;54:1712]. Neurology 1999;53:1731–1735.PubMedGoogle Scholar
  51. 51.
    Kawai K, Shimizu H, Maehara T, Murakami H. Outcome of long-term vagus nerve stimulation for intractable epilepsy. Neurol Med Chir (Tokyo) 2002;42:481–489; discussion 490.CrossRefGoogle Scholar
  52. 52.
    Scherrmann J, Hoppe C, Kral T, Schramm J, Elger CE. Vagus nerve stimulation: clinical experience in a large patient series. J Clin Neurophysiol 2001;18:408–414.PubMedCrossRefGoogle Scholar
  53. 53.
    Spanaki MV, Allen LS, Mueller WM, Morris GL 3rd. Vagus nerve stimulation therapy: 5-year or greater outcome at a university-based epilepsy center. Seizure 2004;13:587–590.PubMedCrossRefGoogle Scholar
  54. 54.
    Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs. Seizure 2004;13: 392–398.PubMedCrossRefGoogle Scholar
  55. 55.
    Heck C, Helmers SL, DeGiorgio CM. Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology 2002;59 Suppl 4:S31-S37.PubMedGoogle Scholar
  56. 56.
    Homig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J 1997;90:484–488.Google Scholar
  57. 57.
    Alexopoulos AV, Kotagal P, Loddenkemper T, Hammel J, Bingaman WE. Long-term results with vagus nerve stimulation in children with pharmacoresistant epilepsy. Seizure 2006;15:491–503.PubMedCrossRefGoogle Scholar
  58. 58.
    Hallböök T, Lundgren J, Stjernqvist K, Blennow G, Strömblad LG, Rosen I. Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood. Seizure 2005;14:504–513.PubMedCrossRefGoogle Scholar
  59. 59.
    Patwardhan RV, Stong B, Bebin EM, Mathisen J, Grabb PA. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery 2000;47:1353–1357; discussion 1357–1358.PubMedCrossRefGoogle Scholar
  60. 60.
    Hosain S, Nikalov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000;15:509–512.PubMedCrossRefGoogle Scholar
  61. 61.
    Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148–1152.PubMedCrossRefGoogle Scholar
  62. 62.
    Michaud CM, Murray CJ, Bloom BR. Burden of disease: implications for future research. JAMA 2001;285:535–539.PubMedCrossRefGoogle Scholar
  63. 63.
    Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095–3105.PubMedCrossRefGoogle Scholar
  64. 64.
    Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry 2006; 163:1362–1370.PubMedCrossRefGoogle Scholar
  65. 65.
    American Psychiatric Association; American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.Google Scholar
  66. 66.
    Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61 Suppl 1:17–25.PubMedGoogle Scholar
  67. 67.
    Simon GE. Social and economic burden of mood disorders. Biol Psychiatry 2003;54:208–215.PubMedCrossRefGoogle Scholar
  68. 68.
    Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16–31.PubMedCrossRefGoogle Scholar
  69. 69.
    Rasmussen KG, Sampson SM, Rummans TA. Electroconvulsive therapy and newer modalities for the treatment of medication-refractory mental illness. Mayo Clin Proc 2002;77:552–556.PubMedCrossRefGoogle Scholar
  70. 70.
    Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004;55:301–312.PubMedCrossRefGoogle Scholar
  71. 71.
    Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000;42:203–210.PubMedCrossRefGoogle Scholar
  72. 72.
    Rawlins P. Are there benefits, in addition to seizure control, for children receiving vagus nerve stimulation? Epilepsia 1997; 38(Suppl 8):155–156.Google Scholar
  73. 73.
    Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 1996; 128:115–129.CrossRefGoogle Scholar
  74. 74.
    Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998;59:426–429.PubMedCrossRefGoogle Scholar
  75. 75.
    O’Reardon JP, Cristancho P, Peshek AD. Vagal nerve stimulation and treatment of depression: to the brainstem and back. Psychiatry 2006;3:54–63.PubMedGoogle Scholar
  76. 76.
    Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001;25:713–728.PubMedCrossRefGoogle Scholar
  77. 77.
    Bohning DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI. Invest Radiol 2001;36: 470–479.PubMedCrossRefGoogle Scholar
  78. 78.
    Lomarev M, Denslow S, Nahas Z, Chae JH, George MS, Bohning DE. Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency/dose dependent effects. J Psychiatr Res 2002;36:219–227.PubMedCrossRefGoogle Scholar
  79. 79.
    Conway CR, Sheline YI, Chibnall JT, George MS, Fletcher JW, Mintun MA. Cerebral blood flow changes during vagus nerve stimulation for depression. Psychiatry Res 2006;146:179–184.PubMedCrossRefGoogle Scholar
  80. 80.
    Zobel A, Joe A, Freymann N, et al. Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach. Psychiatry Res 2005;139:165–179.PubMedCrossRefGoogle Scholar
  81. 81.
    Mayberg HS. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003;13:805–815.PubMedCrossRefGoogle Scholar
  82. 82.
    Krahl SE, Senanayake SS, Pekary AE, Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res 2004;38:237–240.PubMedCrossRefGoogle Scholar
  83. 83.
    Doit AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006;318:890–898.CrossRefGoogle Scholar
  84. 84.
    Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000;47:276–286.PubMedCrossRefGoogle Scholar
  85. 85.
    Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66:1097–1104.PubMedCrossRefGoogle Scholar
  86. 86.
    Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 2002;51:280–287.PubMedCrossRefGoogle Scholar
  87. 87.
    George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364–373.PubMedCrossRefGoogle Scholar
  88. 88.
    Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285:1299–1307.PubMedCrossRefGoogle Scholar
  89. 89.
    Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58:355–363.PubMedCrossRefGoogle Scholar
  90. 90.
    Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347–354.PubMedCrossRefGoogle Scholar
  91. 91.
    Smyth MD, Tubbs RS, Bebin EM, Grabb PA, Blount JP. Complications of chronic vagus nerve stimulation for epilepsy in children. J Neurosurg 2003;99:500–503.PubMedCrossRefGoogle Scholar
  92. 92.
    MacDonald J, Couldwell WT. Revision of vagal nerve stimulator electrodes: technical approach. Acta Neurochir (Wien) 2004;146:567–570; discussion 570.CrossRefGoogle Scholar
  93. 93.
    Ramsay RE, Uthman BM, Augustinsson LE, et al.; First International Vagus Nerve Stimulation Study Group. Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. Epilepsia 1994;35: 627–636.PubMedCrossRefGoogle Scholar
  94. 94.
    Kim W, Clancy RR, Liu GT. Homer syndrome associated with implantation of a vagus nerve stimulator. Am J Ophthalmol 2001; 131:383–384.PubMedCrossRefGoogle Scholar
  95. 95.
    Lundy DS, Casiano RR, Landy HJ, Gallo J, Gallo B, Ramsey RE. Effects of vagal nerve stimulation on laryngeal function. J Voice 1993;7:359–364.PubMedCrossRefGoogle Scholar
  96. 96.
    Zumsteg D, Jenny D, Wieser HG. Vocal cord adduction during vagus nerve stimulation for treatment of epilepsy. Neurology 2000;54:1388–1389.PubMedGoogle Scholar
  97. 97.
    Shaffer MJ, Jackson CE, Szabo CA, Simpson CB. Vagal nerve stimulation: clinical and electrophysiological effects on vocal fold function. Ann Otol Rhinol Laryngol 2005;114:7–14.PubMedGoogle Scholar
  98. 98.
    Shaw GY, Sechtem P, Searl J, Dowdy ES. Predictors of laryngeal complications in patients implanted with the Cyberonics vagal nerve stimulator. Ann Otol Rhinol Laryngol 2006;115:260–267.PubMedGoogle Scholar
  99. 99.
    Wakai S, Kotagal P. Vagus nerve stimulation for children and adolescents with intractable epilepsies. Pediatr Int 2001;43:61–65.PubMedCrossRefGoogle Scholar
  100. 100.
    Farooqui S, Boswell W, Hemphill JM, Pearlman E. Vagus nerve stimulation in pediatric patients with intractable epilepsy: case series and operative technique. Am Surg 2001;67:119–121.PubMedGoogle Scholar
  101. 101.
    Majoic HJ, Berfelo MW, Aldenkamp AP, Renier WO, Kessels AG. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure 2005;14:10–18.CrossRefGoogle Scholar
  102. 102.
    Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 2001;16:843–848.PubMedCrossRefGoogle Scholar
  103. 103.
    Chavel SM, Westerveld M, Spencer S. Long-term outcome of vagus nerve stimulation for refractory partial epilepsy. Epilepsy Behav 2003;4:302–309.PubMedCrossRefGoogle Scholar
  104. 104.
    Hui AC, Lam JM, Wong KS, Kay R, Poon WS. Vagus nerve stimulation for refractory epilepsy: long term efficacy and side-effects. Chin Med J (Engl) 2004;117:58–61.Google Scholar
  105. 105.
    Holmes MD, Silbergeld DL, Drouhard D, Wilensky AJ, Ojemann LM. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure 2004;13:340–345.PubMedCrossRefGoogle Scholar
  106. 106.
    Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. Epilepsy Behav 2005;6:417–423.PubMedCrossRefGoogle Scholar
  107. 107.
    Rychlicki F, Zamponi N, Trignani R, Ricciuti RA, Iacoangeli M, Scerrati M. Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients. Seizure 2006;15:483–490.PubMedCrossRefGoogle Scholar
  108. 108.
    Saneto RP, Sotero de Menezes MA, Ojemann JG, et al. Vagus nerve stimulation for intractable seizures in children. Pediatr Neurol 2006;35:323–326.PubMedCrossRefGoogle Scholar
  109. 109.
    De Herdt V, Boon P, Ceulemans B, et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol 2007;11:261–269.PubMedCrossRefGoogle Scholar
  110. 110.
    Kostov H, Larsson PG, Roste GK. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta Neurol Scand Suppl 2007;187:55–58.PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2008

Authors and Affiliations

  • Andrew H. Milby
    • 1
  • Casey H. Halpern
    • 1
  • Gordon H. Baltuch
    • 1
  1. 1.Department of Neurosurgery, Center for Functional and Restorative NeurosurgeryUniversity of Pennsylvania Medical CenterPhiladelphia

Personalised recommendations